Does Prevention and Therapy Save Follow-up Costs in Type 2 Diabetes? Computer Models with Virtual Patients are Succeeding Large Intervention Trials;Sparen Prävention und Therapie Folgekosten beim Typ-2-Diabetes ein?

Diabetologie und Stoffwechsel

Volumn 1, Issue 4, 2006, Pages 245-251

  Biermann, E ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

cost effectiveness; cost utility; lifesyle; screening; type 2 diabetes

Indexed keywords

EID: 36248933322     PISSN: 18619002     EISSN: 18619010     Source Type: Journal    
DOI: 10.1055/s-2006-947206     Document Type: Article

References (25)

1. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998; 352: 837–853
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high risk conditions. Lancet, 2004; 363: 757–767
3. Montori VM, Amiram G, Charles C. A shared treatment decision-making approach between patients with chronic conditions and their clinicians: the case of diabetes. Health Expectations, 2006; 9: 25–36
4. Steckelberg A, Berger B, Köpke S, Heesen Ch, Mühlhauser I. Kriterien für evidenzbasierte Patienteninformationen. Z ärztl Fortbild Qual Gesundheitswesen 2005; 99: 343–351
5. Siebert U. Transparente Entscheidungen in Public Health mittels sys-tematischer Entscheidungsanalyse. Aus: Schwartz FW et.al. (Hrsg.). Das Public Health Buch München-Jena: Urban & Fischer, 2003: 67–89
6. Schramm W, Schöffski O, Görtz A, Liebl A. Erkrankungsmodellierung bei Diabetes mellitus. Dtsch med Wochenschr 2004; 129: 2305–2310
7. Kobelt G. Modelle als Instrument der Gesundheitsökonomie. Gesund Ökonomie Qualitätsmanagement 2005; 10 (Supp 2): S32–36
8. O'Sullivan AK, Thompson D, Drummond MF. Collection of Health-Economic Data Alongside Clinical Trials: Is There a Future for Piggyback Evaluations? Value in Haelth 2005; 8: 67–79
9. Hoerger ThJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis. Ann Intern Med. 2004; 140:689–699
10. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344: 1343–1350
11. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention. N Engl J Med. 2002; 346: 393–403
12. Herman WH et al. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance. Ann Intern Med 2005; 142: 323–332
13. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003; 26: 3093–3101
14. Eddy DM, Schlessinger L, Kahn R. Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes. Ann Intern Med 2005; 143: 251–264
15. Herman W et al. Response: Managing People at High Risk for Diabetes. Annals of Internal Medicine 2006; 144: 65–67
16. THE DIABETES PREVENTION PROGRAM RESEARCH GROUP Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention of Type 2. Diabetes Care, 2003; 26: 2518–2523
17. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005; 48: 868–877
18. The CDC-Costeffectiveness Group (Hoerger), Cost-Effectiveness of intensive glycemic control, inetsive hypertension control and serum cholesterol reduction for type-2-diabetes. JAMA, 2002; 287: 19–25
19. Grover SA et al. How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease. Diabetes Care 2001; 24: 45–50
20. Stock SAK, Redaelli M, Wendland G, Civello D, Lauterbach KW. Diabetes-prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med 2006; 23:299–305
21. Schlander M. Zur Logik der Kosteneffektivität. Dtsch Ärztebl 2003; 100: A2140–2141
22. Rohrbacher R. Modellierung als Grundlage für die Erstattung medizinischer Leistungen, eine internationale Perspektive. Gesund Ökonomie Qualitätsmanagement 2005; 10(Supp2): S45–51
23. Roper NA, Bilous RW, Kelly WF et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001; 322: 1389–1393
24. Muir Gray JA. Evidence-based Healthcare. Churchill Livingstone: 2001:209–218
25. Heart Protection Study Collaborative Group. Cost-effectiveness of simuastatin in people of different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals. Lancet, 2005; 365: 1779–1785